True

Abstract

Currently the only tumour marker to have a well-defined and validated role in the management of ovarian cancer is CA125. Changes in the level of CA125 can be used as a reliable indication of response or progression according to various criteria, but it does not yet have a clear place in diagnosis or prognosis. Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present.

References 34

1. 1.

   Bast R. C., Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331-1337.

   Not in our library10.1172/jci110380

2. 2.

   Bast R. C., Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883-887.

   Not in our library10.1056/nejm198310133091503

3. 3.

   Bridgewater J. A., Nelstrop A. E., Rustin G. J., Gore M. E., McGuire W. P., Hoskins W. J. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999;17(2):501-508.

   Not in our library10.1200/jco.1999.17.2.501

4. 4.

   Buller R. E., Berman M. L., Bloss J. D., Manetta A., DiSaia P. J. Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol. 1992;47(1):87-92.

   Not in our library10.1016/0090-8258(92)90082-t

5. 5.

   Davelaar E. M., Bonfrer J. M., Verstraeten R. A., ten Bokkel Huinink W. W., Kenemans P. CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer. 1996;78(1):118-127.

   Not in our library10.1002/(sici)1097-0142(19960701)78:1<118::aid-cncr17>3.0.co;2-2

6. 6.

   Einhorn N., Sjövall K., Knapp R. C., Hall P., Scully R. E., Bast R. C., Zurawski V. R. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992;80(1):14-18.

   Not in our library

7. 7.

   Eisenhauer E. A., Vermorken J. B., van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol. 1997;8(10):963-968.

   Not in our library10.1023/a:1008240421028

8. 8.

   Fayers P.M., Rustin G., Wood R., Nelstrop A., Leonard R.C.F., Wilkinson P., Cruickshank D., McAllister E.J., Redman C.W.E., Parker D. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer. 1993;3(5):285-292.

   Not in our library10.1046/j.1525-1438.1993.03050285.x

9. 9.

   Gadducci A., Baicchi U., Marrai R., Ferdeghini M., Bianchi R., Facchini V. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol. 1996;60(2):197-202.

   Not in our library10.1006/gyno.1996.0025

10. 10.

    Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lowe D. G. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207-1210.

    Not in our library10.1016/s0140-6736(98)10261-1

11. 11.

    Jacobs I., Davies A. P., Bridges J., Stabile I., Fay T., Lower A., Grudzinskas J. G., Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306(6884):1030-1034.

    Not in our library10.1136/bmj.306.6884.1030

12. 12.

    Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J. G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922-929.

    Not in our library10.1111/j.1471-0528.1990.tb02448.x

13. 13.

    Jacobs I., Stabile I., Bridges J., Kemsley P., Reynolds C., Grudzinskas J., Oram D. Multimodal approach to screening for ovarian cancer. Lancet. 1988;1(8580):268-271.

    Not in our library10.1016/s0140-6736(88)90351-0

14. 14.

    Krebs H. B., Goplerud D. R., Kilpatrick S. J., Myers M. B., Hunt A. Role of Ca 125 as tumor marker in ovarian carcinoma. Obstet Gynecol. 1986;67(4):473-477.

    Not in our library

15. 15.

    Lavin P. T., Knapp R. C., Malkasian G., Whitney C. W., Berek J. C., Bast R. C. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987;69(2):223-227.

    Not in our library

16. 16.

    Markman M. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer. Gynecol Oncol. 1993;51(3):297-298.

    Not in our library10.1006/gyno.1993.1292

17. 17.

    Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214.

    Not in our library10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6

18. 18.

    Nagele F., Petru E., Medl M., Kainz C., Graf A. H., Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995;86(2):259-264.

    Not in our library10.1016/0029-7844(95)00126-c

19. 19.

    Ng L. W., Homesley H. D., Barrett R. J., Welander C. E., Case L. D. CA-125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. Am J Clin Oncol. 1989;12(2):106-109.

    Not in our library10.1097/00000421-198904000-00003

20. 20.

    Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.

    Not in our library

21. 21.

    Pearl M. L., Yashar C. M., Johnston C. M., Reynolds R. K., Roberts J. A. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol. Gynecol Oncol. 1994;53(3):339-343.

    Not in our library10.1006/gyno.1994.1144

22. 22.

    Rustin G. J., Nelstrop A. E., McClean P., Brady M. F., McGuire W. P., Hoskins W. J., Mitchell H., Lambert H. E. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14(5):1545-1551.

    Not in our library10.1200/jco.1996.14.5.1545

23. 23.

    Rustin G. J., Nelstrop A. E., Tuxen M. K., Lambert H. E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7(4):361-364.

    Not in our library10.1093/oxfordjournals.annonc.a010602

24. 24.

    Rustin G. J., Nelstrop A., Stilwell J., Lambert H. E. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer. 1992;28(1):79-82.

    Not in our library10.1016/0959-8049(92)90390-n

25. 25.

    Rustin G. J., van der Burg M. E., Berek J. S. Advanced ovarian cancer. Tumour markers. Ann Oncol. 1993;4(Suppl 4):71-77.

    Not in our library

26. 26.

    Sevelda P., Schemper M., Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1989;161(5):1213-1216.

    Not in our library10.1016/0002-9378(89)90668-6

27. 27.

    Sier C. F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N., Frigerio L., Ferrari A., Danø K., Brünner N. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998;58(9):1843-1849.

    Not in our library

28. 28.

    Skates S. J., Xu F. J., Yu Y. H., Sjövall K., Einhorn N., Chang Y., Bast R. C., Knapp R. C. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(10 Suppl):2004-2010.

    Not in our library10.1002/1097-0142(19951115)76:10+<2004::aid-cncr2820761317>3.0.co;2-g

29. 29.

    Tuxen M. K., Sölétormos G., Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21(3):215-245.

    Not in our library10.1016/0305-7372(95)90002-0

30. 30.

    Woolas R. P., Conaway M. R., Xu F., Jacobs I. J., Yu Y., Daly L., Davies A. P., O'Briant K., Berchuck A., Soper J. T. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol. 1995;59(1):111-116.

    Not in our library10.1006/gyno.1995.1276

31. 31.

    Woolas R. P., Xu F. J., Jacobs I. J., Yu Y. H., Daly L., Berchuck A., Soper J. T., Clarke-Pearson D. L., Oram D. H., Bast R. C. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993;85(21):1748-1751.

    Not in our library10.1093/jnci/85.21.1748

32. 32.

    Xu F. J., Yu Y. H., Daly L., DeSombre K., Anselmino L., Hass G. M., Berchuck A., Soper J. T., Clarke-Pearson D. L., Boyer C. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol. 1993;11(8):1506-1510.

    Not in our library10.1200/jco.1993.11.8.1506

33. 33.

    van der Burg M. E., Lammes F. B., Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol. 1990;1(4):301-302.

    Not in our library10.1093/oxfordjournals.annonc.a057754

34. 34.

    van der Burg M. E., Lammes F. B., van Putten W. L., Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol. 1988;30(3):307-312.

    Not in our library10.1016/0090-8258(88)90244-2

Cited by papers we hold 4

• ROLE OF INTEGRATED PET/CT IN DETECTING RECURRENT OVARIAN CANCER IN PATIENTS WITH RISING CA-125 LEVELS · 2015
  Not checked
• Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers · 2015
  No notice
• Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature · 2009
  No notice
• Circulating Haptoglobin Is an Independent Prognostic Factor in the Sera of Patients with Epithelial Ovarian Cancer · 2007
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.